greeksoup/ stock research

Roivant Sciences (ROIV) FY2022 results: revenue $32 million, down 43.0% on the year

Roivant Sciences Ltd. (ROIV) reported revenue of $32 million for fiscal 2022, the year ended 31 March 2023, down 43.0% on the year before. Net income was -$1.0 billion, and diluted earnings per share $-1.42. The figures are the company's own, from the 10-K it filed with the SEC on 28 June 2023.

Revenue
$32 million
-43.0% on the year
FY2020FY2022
Operating margin
-2875.9%
-2444.8% a year earlier
FY2020FY2022
Net income
-$1.0 billion
FY2020FY2022
Diluted EPS
-$1.42
FY2020FY2022

this yearthe year beforeHover a bar for its figure.

The year in brief

The four quarters: Q1 FY2022 · Q2 FY2022 · Q3 FY2022 · Q4 FY2022

Income statement (profit and loss)

$ millionFY2022FY2021FY2020On the yearLast 8 years
Revenue31.555.323.8-43.0%
Research and development454483237-6.0%
Selling, general and administrative601775n/a-22.5%
Operating income-907-1,352-1,071
Operating margin-2875.9%-2444.8%-4500.5%
Interest expense28.07.02.8+297.2%
Pre-tax income-885-924-899
Income tax4.10.41.7+1,006.2%
Net income-1,009-845-809
Net margin-3200.2%-1528.9%-3400.9%
Diluted EPS-$1.42-$1.26-$1.28
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2022FY2021FY2020On the yearLast 8 years
Operating cash flow-843-678-552
Capital expenditure12.717.45.8-27.2%
Free cash flow-856-695-558
Free cash flow margin-2715.1%-1257.4%-2344.8%
Cash from investing-44.3303-31.7
Cash from financing499307456+62.8%
Depreciation and amortisation18.95.9n/a+217.9%
Share-based compensation21856585.0-61.5%
Buybacks0.0n/an/a
Diluted shares, weighted713m670mn/a+6.4%
Shares outstanding at period end760m695m223m+9.4%

Balance sheet

$ millionFY2022FY2021FY2020On the yearLast 8 years
Shareholders' equity1,1581,6571,798-30.1%
Non-controlling interest450382242+17.8%
Redeemable equity0.022.522.5
Short-term borrowingsn/a0.0n/a
Debt416210170+98.2%
Operating lease liabilities53.562.562.4-14.4%
Finance lease liabilities3.6n/an/a
Other liabilities309251295+22.9%
Total liabilities and equity2,3902,5852,590-7.6%
Fixed assets39.125.914.7+50.9%
Intangible assets1450.0n/a
Investmentsn/a0.0101
Cash and equivalents1,6772,0602,055-18.6%
Receivables30.43.911.2+683.4%
Inventory2.80.0n/a
Other assets496495408+0.1%
Total assets2,3902,5852,590-7.6%

10-K for the year ended 31 March 2023, filed 28 June 2023: the filing.